LONGEVITY & CELLULAR HEALTH / FAQ
Questions from the Science
Direct, citation-grounded answers to the questions people most often bring to NAD+ and MOTS-c.
What is NAD supplement used for?
In the research context, NAD+ precursor supplements (chiefly NMN and NR) are studied for their ability to raise blood NAD+ levels and, by extension, to support the sirtuin, PARP, and metabolic pathways that NAD+ serves as a substrate or coenzyme. Clinical trials have found that oral NMN dose-dependently raised blood NAD+ and improved walking distance and quality-of-life scores in middle-aged adults [2], and that NMN improved muscle insulin sensitivity in prediabetic postmenopausal women [3]. Whether these blood-level and functional improvements translate to longer-term aging or disease outcomes in humans has not yet been demonstrated; a 2025 review concluded the human efficacy data remain limited [1]. This site describes the research record; it does not recommend supplement use.
What is the downside of taking NAD+?
Several cautions follow directly from the published literature. Plain oral NAD+ capsules are considered by most experts to be poorly effective because NAD+ as a molecule does not cross cell membranes intact — precursors (NMN, NR) are the rational oral approach [4]. IV-infused NAD+ can cause chest discomfort, flushing, and nausea if administered too quickly, and compounded injectable NAD+ has been subject to a Class I recall for bacterial endotoxin contamination [4]. A theoretical concern exists that chronically elevated NAD+ could support the metabolism of pre-existing cancer cells, given NAD+'s role in cellular proliferation; cancer populations warrant particular caution [4]. Supplement quality is variable; regulatory status of NMN specifically is contested. None of this is medical advice.
Is it safe to take NAD daily?
The human trial data available suggest that oral NMN and NR are well tolerated at the doses studied. In a multicenter double-blind RCT, oral NMN at 300, 600, or 900 mg/day for 60 days produced no safety issues at any dose [2]. NR at 100, 300, and 1000 mg/day for 8 weeks produced no significant adverse-event differences from placebo, no flushing, and no changes in cholesterol or one-carbon metabolism [5]. The 2025 review calls for more clinical studies rather than raising an alarm about short-term oral safety [1]. Long-term safety in humans is genuinely less established — particularly for high-dose, prolonged, or intravenous use. This desk describes the research record and does not advise on supplement regimens.
Does NAD cause weight gain?
The published trial evidence does not support a link between NAD+ precursor supplementation and weight gain. In the multicenter NMN trial, body composition did not change significantly over 60 days [2]. In the NMN insulin-sensitivity trial in prediabetic women, body composition also did not change [3]. The NR dose-escalation trial found no adverse metabolic changes including no change in LDL cholesterol at doses up to 1000 mg/day [5]. A mechanistic argument would actually point the other direction — NAD+ precursors have been studied partly for metabolic benefit including improved insulin sensitivity — but the human data on body weight and composition are mixed and not a primary endpoint in most trials. This site does not advise on supplement use.
What does the MOTS-c peptide do?
MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome that improves cellular energy handling primarily in skeletal muscle. Its best-characterized mechanism: it inhibits the folate cycle, causing AICAR to accumulate, which activates AMP-activated protein kinase (AMPK) — a master fuel sensor that promotes glucose uptake and efficient energy use [11]. Under metabolic stress it also translocates from the mitochondrion to the nucleus and influences gene expression through the antioxidant-response pathway [10]. In animal models it has prevented diet-induced obesity and insulin resistance [11], extended physical performance in aged mice [9], and protected the diabetic heart [12]. In humans, circulating MOTS-c has associated independently with cardiovascular mortality risk in a high-risk patient cohort [7]. No human interventional trials of exogenous MOTS-c have been published.
What are the negative side effects of MOTS-c?
Because no human interventional trials of exogenous MOTS-c have been completed, the human safety profile of the peptide as administered externally is genuinely unknown [8]. The cautions that do appear in the research literature are: no validated human pharmacokinetics (rodent doses cannot be extrapolated to humans); research-chemical status means product purity and sterility from commercial suppliers are unregulated; anti-doping prohibition means athletes face serious sanction risk; and a genetic variant of the MOTS-c gene (m.1382A>C) has been described as pro-diabetogenic, suggesting effects may not be uniform across populations or genotypes [8]. The absence of side-effect data in humans is not evidence of safety — it is evidence of an early stage of research. Nothing on this site is medical advice.
Is MOTS-c legal to buy?
In most jurisdictions, purchasing MOTS-c as a research chemical from a laboratory supplier is not illegal, but the legal and practical context has several layers. MOTS-c is not an approved drug or dietary supplement in any major jurisdiction, meaning it cannot lawfully be sold for human consumption — only for laboratory research use [8]. In the elite sport context, it is treated as a prohibited substance under WADA anti-doping frameworks covering peptide hormones and metabolic modulators, and athlete possession or use can result in formal sanctions [8]. Buyers should understand that they are purchasing an unregulated research chemical with no standardized purity requirements, no validated human safety profile, and no approved use. This desk does not facilitate or encourage purchase.
How often do you inject MOTS-c?
This site does not advise on injection frequency, dosing schedules, or routes of administration for MOTS-c or any other compound. There is no validated human dosing protocol for MOTS-c — no published clinical trial has established a human dose, frequency, or route [8]. Animal studies have used varying doses and schedules that cannot be extrapolated to humans. Community-circulating protocols have no peer-reviewed basis. The research literature is unambiguous on this point: MOTS-c is at a stage where basic human pharmacokinetics have not yet been formally characterized. Anyone seeking dosing guidance for a medical purpose should consult a licensed clinician operating within their own jurisdiction and regulatory framework.
What is the difference between NAD+ and MOTS-c?
The two molecules are fundamentally different in nature, mechanism, and evidence stage. NAD+ is a dinucleotide — a ubiquitous coenzyme every cell has always made — that functions as both a redox carrier (shuttling electrons to generate ATP) and a consumed substrate for sirtuin and PARP signaling enzymes [4]. MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome that acts as a metabolic stress signal: it activates AMPK via the folate cycle, translocates to the nucleus under stress, and has a direct molecular target in casein kinase 2 [6][10][11]. In terms of human evidence, NAD+ precursors have been through multiple randomized trials; MOTS-c has one human biomarker-association study [7] and no interventional trials. The compare page has the full side-by-side.
Can NAD+ and MOTS-c be taken together?
The research literature does not contain human studies of NAD+ precursors and MOTS-c in combination, so no evidence-based answer is possible. MOTS-c is not a substance with an established human protocol of any kind [8], and the theoretical interactions with NAD+ metabolism — while mechanistically interesting, given that MOTS-c activates AMPK which itself regulates NAD+ biosynthesis pathways — have not been studied in humans. This site does not advise on supplement stacking, regimen design, or combination use. Nothing here is medical advice.
Are there human trials on longevity peptides like MOTS-c?
For MOTS-c specifically, no completed human interventional trials exist; the strongest human data are a single biomarker-association cohort study in hemodialysis patients [7]. For NAD+ precursors there are multiple randomized controlled trials, though these have focused on surrogate endpoints (blood NAD+ levels, insulin sensitivity, walking distance) rather than longevity itself [1][2][3]. The 2025 Nature Metabolism review on NAD+ supplementation concluded that the human evidence base, while growing, still shows limited efficacy and calls for more rigorous studies of tissue-specific NAD+ dynamics [1]. Across the longevity research field more broadly, the honest summary is: compelling mechanisms, consistent preclinical data, and human outcome evidence that is still building.